稳律平悸颗粒对心房颤动心肌纤维化干预效应的CMR T1 mapping定量评估

王新东; 孙雪梅; 方祝元

稳律平悸颗粒对心房颤动心肌纤维化干预效应的CMR T1 mapping定量评估

1.
江苏省中西医结合医院心血管科，江苏南京 210028
2.
南京中医药大学附属医院/江苏省中医院，江苏南京 210029

计量
- 文章访问数: 444
- HTML全文浏览量: 5
- PDF下载量: 346
- 被引次数: 0
出版历程
- 刊出日期: 2020-05-10

Quantitative Assessment of CMR T1 Mapping on the Interventional Effects of Wenlü Pingji Granule on Myocardial Fibrosis and Atrial Fibrillation

1.
Cardiovascular Department, Jiangsu Province Hospital of Integrated Chinese and Western Medicine, Nanjing, 210028, China
2.
Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China

摘要

摘要: 目的运用心脏磁共振纵向弛豫时间（CMR T1 mapping）定量评估稳律平悸颗粒对心房颤动气阴两虚证患者左心室心肌纤维化的干预效应。方法选取2017年3月至2019年11月符合纳入标准的房颤气阴两虚证患者43例（持续性房颤17例、阵发性房颤26例），随机分为西药治疗对照组（20例）和经验方稳律平悸颗粒治疗中药组（23例），治疗及观察周期24周。采用CMR T1 mapping成像定量评估治疗后左心室心肌纤维化，ELISA法检测血清白介素-18（IL-18）、肿瘤坏死因子-α（TNF-α）、超氧化物歧化酶（SOD）、丙二醛（MDA）、肝激酶B1（LKB1）水平和纤维化指标基质金属蛋白酶2（MMP-2）、Ⅲ型前胶原氨基末端肽（PⅢNP）以评估房颤纤维化上游氧化炎症相关因子的变化。结果中药组阵发性房颤患者房颤的复发次数和复发率均低于对照组（P<0.05）。中药组治疗后T1值和ECV均明显下降（P<0.01），血清MMP-2、PⅢNP、IL-18、TNF-α、MDA 水平显著降低（P<0.01），SOD和LKB1水平显著升高（P<0.01），优于西药对照组（P<0.01）。结论稳律平悸颗粒有助于阵发性房颤患者窦律维持、减少复发，可抑制房颤气阴两虚证患者心肌纤维化，机制可能与抑制上游氧化炎症级联有关。
- 稳律平悸颗粒 /
- 心房颤动 /
- 气阴两虚证 /
- 心肌纤维化 /
- 心脏磁共振纵向弛豫时间定量成像
Abstract: OBJECTIVE To observe the quantitative assessment of cardiac magnetic resonance longitudinal relaxation time (CMR T1 mapping) on the interventional effect of Wenlü Pingji Granule on patients with atrial fibrillation (deficiency of both qi and yin) in terms of left ventricular myocardial fibrosis. METHODS 43 patients with atrial fibrillation with deficiency of qi and yin syndrome who met the inclusion criteria from March 2017 to November 2019， including 17 cases of persistent atrial fibrillation and 26 cases of paroxysmal atrial fibrillation. They were randomly divided into western medicine control group (20 cases) and Chinese medicine group (23 cases) applied with Wenlü Pingji Granule. The treatment and observation period was 24 weeks. The left ventricular myocardial fibrosis after treatment was quantitatively assessed by CMR T1 mapping imaging. ELISA was applied to detect serum interleukin 18 (IL-18)， tumor necrosis factor-α (TNF-α)， superoxide dismutase (SOD)， malondialdehyde (MDA)， liver kinase B1 (LKB1) levels and fibrosis indicator matrix metalloproteinase-2 (MMP-2)， pre-collagen amino terminal peptide Ⅲ (PⅢ NP) so as to assess the changes of upstream oxidative inflammation-related factors in atrial fibrillation fibrosis. RESULTS The number of recurrence frequency and rate of atrial fibrillation in patients with paroxysmal atrial fibrillation in the Chinese medicine group were lower than those in the control group (P<0.05). The T1 value and ECV were significantly decreased (P<0.01)， serum MMP-2， PⅢ NP， IL-18， TNF-α and MDA levels were significantly decreased (P<0.01) and SOD and LKB1 levels were significantly increased (P<0.01) after treatment in the Chinese medicine group， which were better than those in the western medicine control group (P<0.01). CONCLUSION Wenlü Pingji Granule can keep Sinus rhythm maintenance and reduce recurrence in patients with paroxysmal atrial fibrillation， as well as inhibit myocardial fibrosis in atrial fibrillation patients with deficiency of qi and yin syndrome. The mechanism may be related to the inhibition of the upstream oxidative inflammatory cascade.
- Wenlü Pingji Granule /
- atrial fibrillation /
- deficiency of qi and yin syndrome /
- myocardial fibrosis /
- cardiac magnetic resonance longitudinal relaxation time quantitative imaging

HTML全文

参考文献(14)

[1]	WONG CX， LAU DH， SANDERS P. Atrial fibrillation epidemic and hospitalizations: How to turn the rising tide[J]. Circulation， 2014， 129(23): 2361-2363.
[2]	KOTTKAMP H， SCHREIBER D， MOSER F， et al. Therapeutic approaches to atrial fibrillation ablation targeting atrial fibrosis[J]. JACC Clin Electrophysiol， 2017，3(7):643-653.
[3]	JANUARY CT， WANN LS， ALPERT JS， et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation，2014， 130(23):199-267.
[4]	中华人民共和国国家质量监督检验检疫总局，中国国家标准化管理委员会. 中华人民共和国国家标准——中医临床诊疗术语·证候部分[S].北京:中国标准出版社，1997:80.
[5]	HWANG IC， KIM HK， PARK JB， et al. Aortic valve replacement-induced changes in native T1 are related to prognosis in severe aortic stenosis: T1 mapping cardiac magnetic resonance imaging study[J]. Eur Heart J Cardiovasc Imag， 2019， 2019，pii: jez201.
[6]	沈卫峰，贝政平，汤如勇. 心血管病诊疗标准[M].上海:上海科学普及出版社，1991:122-123.
[7]	中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社，1993:59-60.
[8]	BENJAMIN EJ， WOLF PA， D'AGOSTINO RB， et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study[J]. Circulation， 1998，98(10):946-952.
[9]	OUYANG F， TILZ R， CHUN J， et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: Lessons from a 5-year follow-up[J]. Circulation， 2010，122(23):2368-2377.
[10]	ALLESSIE MA， BOYDEN PA， CAMM AJ， et al. Pathophysiology and prevention of atrial fibrillation[J]. Circulation， 2001， 103(5):769-777.
[11]	马晓海，赵蕾，李松南，等.心房颤动患者左心室心肌纤维化的MR定量分析研究[J].中国医学影像技术，2017，33(8):1134-1138.
[12]	KORODI S， TOGANEL R， BENEDEK T， et al. Impact of inflammation-mediated myocardial fibrosis on the risk of recurrence after successful ablation of atrial fibrillation - the FIBRO-RISK study: Protocol for a non-randomized clinical trial[J].Medicine (Baltimore)，2019，98(9):e14504.
[13]	KIM GE， ROSS JL， XIE C， et al. LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation[J]. Cardiovasc Res， 2015，108(1):197-208.
[14]	OZCAN C， BATTAGLIA E， YOUNG R， et al. LKB1 knockout mouse develops spontaneous atrial fibrillation and provides mechanistic insights into human disease process[J]. J Am Heart Assoc， 2015， 4(3): e001733.